Introduction: To maximize the benefits of computed tomographic screening for lung cancer, optimal treatment for small, early lung cancers is needed. Limiting the extent of surgery spares lung tissue, preserves pulmonary function, and decreases operative time, complications, and morbidities. It also increases the likelihood of resecting future new primary lung cancers. The goal is to assess alternative treatments in a timely manner.
Introduction
Low-dose computed tomography (CT) screening for lung cancer is now covered for high-risk smokers by private insurers and the Centers for Medicare and Medicaid Services based on the B recommendation given by the United States Preventive Services Task Force. 1 Optimal treatment for small, early-stage lung cancers is needed to maximize the benefits of early detection and diagnosis. Screening for breast cancer resulted in finding smaller, earlier breast cancers which led to profound changes in breast cancer treatment. For breast cancer, treatments evolved from radical mastectomy with extensive axillary lymph node dissection for early-stage disease to more nuanced treatment including lumpectomy and/or radiotherapy over 60 to 79 years. 2 Hopefully, nuanced treatment alternatives for small, early lung cancer identified by CT screening will be integrated into the standard of care more rapidly.
The landmark randomized controlled trial (RCT) comparing lobectomy with sublobar resection as treatment for stage I NSCLCs measuring 3-cm or smaller in all dimensions of posteroanterior and lateral chest radiographs. 3 A total of 276 patients were enrolled over 6 years, from 1982 to 1988, when thoracotomy and chest radiography were the standard of care. It showed that sublobar resection had comparable long-term survival rates to lobectomy but higher recurrence rates. Therefore, lobectomy and mediastinal lymph node resection (MLNR) have remained the standard of care despite remarkable surgical advances, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery. [4] [5] [6] VATS typically resulted in fewer postoperative hospital days and provided better postsurgical quality of life (QoL) than thoracotomy. 4, 5 During this same period, CT scanner technology was introduced and has continued to revolutionize diagnostic imaging. Initially, CT image acquisition was slow; thus, the patient had to take a new breath for each new CT image. Because of this procedure, small cancers could easily be missed due to differences in the patient's inspiratory effort. By the 1990s, technology had advanced sufficiently so that contiguous low-dose CT images of the entire chest could be obtained in a single breath, which made its use for screening for lung cancer realistic. [7] [8] [9] In 2005, a new RCT comparing lobectomy to sublobar resection for stage I NSCLC, 2 cm or less, was started. 10 After a marked reduction in the enrollment goals from 1297 to 692, the target accrual was finally achieved in 2017; however, the earliest primary completion date for this RCT is estimated to be March 2021. This trial again showed the difficulty of randomly assigning patients to alternative treatments when they are diagnosed with an early, potentially curable stage of a deadly disease.
RCTs take a long time to complete as shown by the surgical trials, or may fail to accrue as shown by the trials comparing stereotactic body radiation therapy (SBRT) with surgery. 11 Furthermore, new knowledge emerges while waiting for the results which may ultimately affect its interpretation. One such example is the emerging recognition that certain subtypes of NSCLC are indolent.
12-17 These subtypes were not well understood at the start of the ongoing surgical RCT and thus not considered in the randomization scheme. 10 In the meantime, in the absence of RCT evidence, sublobar resection and focused SBRT are being increasingly used, whereas the use of MLNR is decreasing. [18] [19] [20] [21] The limitations of RCTs were recognized by the Institute of Medicine and the National Cancer Institute in their call for novel alternatives to provide for more rapid evaluation of treatment alternatives, ideally in the context of medical practice. 22, 23 Others also have pointed out the limitations. 24, 25 More recently in 2017, the American Society of Clinical Oncology called for more prospective cohort studies, stating that high-quality observational studies are complementary to RCTs and should be used particularly when RCTs are difficult to perform. 26 In the absence of RCT evidence, meta-analyses have been used to provide recommendations by integrating evidence from multiple individual studies. The Initiative for Early Lung Cancer Research on Treatment (IELCART) investigators performed such an analysis comparing lobectomy with sublobar resection for stage I NSCLC with the hope that it would provide a conclusive answer by focusing on recent studies which used CT imaging and included the latest surgical approaches. 27 Unfortunately, this meta-analysis failed to provide conclusive recommendations because of marked heterogeneity of the individual studies due to lack of standardization of data collection, reporting, and patient selection of the individual studies.
Therefore, we proposed a practice-based prospective cohort study (the IELCART) and present both the process used for its development and our initial feasibility study.
Methods
Once CT screening for lung cancer was recommended for high-risk smokers, discussion at the international conferences on CT screening for lung cancer, held every 6 months, increasingly focused on identifying optimal treatment alternatives. 1, 28 Over time, a multidisciplinary team emerged, and as the meta-analyses did not provide conclusive answers, the team recommended development of a new initiative, heeding the recommendations by the Institute of Medicine, National Cancer Institute, the Journal of Clinical Oncology, and others. [22] [23] [24] [25] [26] 28 The team reviewed existing large databases, including the International Early Lung Cancer Action Program (I-ELCAP) database of screen-diagnosed lung cancers, to gather preliminary evidence for optimal treatment of stage I NSCLC.
Based on these analyses, the team decided on a multiinstitutional prospective cohort design using a common protocol to assess treatment alternatives. Such a study using a prospective cohort design based on data collected as part of actual clinical practice had been used to compare CT with chest radiographic screening. 8 This study, the Early Lung Cancer Action Project (ELCAP), screened a cohort of 1000 participants and its results were sufficiently compelling for the National Cancer Institute to rapidly start a new, very costly screening RCT, the National Lung Screening Trial (NLST), in 2002. 29 ELCAP correctly predicted the results of the NLST. 29 The ELCAP design also allowed for the CT screening protocol to be expanded to multiple institutions which have provided CT screening for more than 80,000 participants in a worldwide collaboration, the I-ELCAP. 9, 30 This approach has allowed for continual updating of the regimen of screening by incorporating new knowledge and technological advances into its protocol so it has remained state-of-the-art. 30 The I-ELCAP database has also provided information on unanticipated findings on the low-dose CT screening scan (e.g., cardiac findings, emphysema, airway wall thickness, interstitial lung disease, breast density, and hepatic steatosis). 30 
Patient Criteria
Patients are eligible for IELCART if they have a first primary clinical stage I NSCLC lung cancer using the Eighth TNM Classification for Lung Cancer. 31 However, different from the Eighth TNM Classification, in IELCART, the tumor size for clinical staging was the average of the length, width, and height measured on the CT image before treatment rather than the largest single dimension. The pathology T staging was as specified in the Eighth TNM Classification which bases the pathology stage using the single largest dimension of the tumor in the pathology specimen.
Treatment
Treatment could be any of treatment alternatives offered at the participating institutions, but treatments had to be documented in detail. Treatments include surgery, SBRT, or no immediate treatment, but rather "watchful waiting." Other treatments being developed can be added.
Outcome Measures
The conceptual model for IELCART analyses of primary and secondary outcomes is shown in Fig. 1 . Primary outcomes are 5-and 10-year survival (vital status) and recurrence rates as well as quality of life measures. Both unadjusted results as well as results adjusted for confounders (e.g., pre-and post-treatment physician, patient responses, and CT scans at enrollment). Outcomes for clinical stage I NSCLC patients who decide not to participate in IELCART will be compared to those who agreed to participate using retrospective de-identified data available in hospital data warehouses and/or cancer registries. Secondary outcomes include complications of treatment, particularly pulmonary problems, such as oxygen dependence, fibrosis, pulmonary hypertension, and other nonpulmonary problems.
IELCART investigators pledged to document manifestations of recurrence or metastases and their timing. These include date and type of recurrence of cancer, including location, for determination of locoregional, distant recurrence, as well as date of any metachronous lung tumor and the frequency of lymph node metastases. Patients will be contacted at a minimum of 6-month intervals during the first year and annually thereafter for up to 10 years. Vital status will be tracked, along with date of last follow-up, date of death, and all causes of death. National Death Index Plus searches will be conducted to determine cause of death, if necessary.
IELCART Management System
In IELCART, quality assurance (QA) is a central concern. QA begins with application of the criteria for data-contributing institutions' admissibility for collaboration. QA is enhanced by the IELCART Coordinating Center which performs central reading of CT image and training and monitoring of site-coordinator performance with corrective actions recommended as needed. A multidisciplinary team of professionals involved in all these aspects meets regularly to review the results to assure quality in implementing the protocol with efficiency and safety. The IELCART web-based interactive Management System was developed to collect data on patients and physicians starting with the initial presurgical patient contact to the end of the long-term follow-up. The system monitors protocol conformity, completeness, and consistency of the data. The data for each participating institution are accessible to each particular institution as well as to the Coordinating Center.
Sample Size Considerations
A non-inferiority trial design comparing KaplanMeier NSCLC survival rates for differences of less than 5% was used to determine the sample size for comparing sublobar resection and SBRT to lobectomy. 32, 33 The target sample size depends on the lung cancer Kaplan-Meier survival rate of lobectomy patients, with lower survival rates requiring larger sample sizes to achieve the same power. The sample size also depends on the ratio of the number of patients having lobectomy to those having alternative treatment, termed the treatment frequency ratios. Sample sizes required to achieve 90% power for four survival rates (65%, 75%, 85%, and 90%), and different treatment frequency ratios were calculated. Assuming survival rates of 65%, the largest sample size required to provide 90% power was 4753 patients. Based on these considerations, we set a target enrollment goal of 5000 clinical stage I NSCLC patients. If the NSCLC survival rate exceeds 65%, then the sample size of 4753 will produce power levels above 90%, or the sample size could potentially be reduced.
Statistical Analysis
The pre-and post-treatment opinions and practices of the treating physician and patients serve as predictors and potential confounders of long-term treatment comparisons. To compare treatment alternatives, innovative analyses are available and more will continue to be developed. [34] [35] [36] We will use propensity analyses approach to emulate an RCT design, assembling a sample in which the observed characteristics of patients are balanced between treatment groups. 34 In cases where appropriate instrumental variables are available, instrumental variable analyses will also be performed to address problems of selection bias. 35 These analyses will address potential known and unknown confounders or potential biases in estimating outcome differences between treatments. Deep learning techniques will be applied to develop prediction model for lung cancer recurrence following treatment, using the CT images and other documented information on each patient. 36 Analyses of trends in QoL will account for both the hierarchical nature of the measurements and potential differential trends due to gender, preoperative QoL, and treatment choices.
Results to Date
The following studies were performed to understand the current practice paradigms and to identify the key questions about optimal treatment of stage I NSCLC. Resection Margin. Analysis of prior data on sublobar resections from I-ELCAP institutions as well as others found that an increasing distance between the cancer and the margin of the resected specimen was associated with lower risk of recurrence (odds ratio ¼ 0.90; 95% confidence interval: 0.83 -0.98), and with longer lungcancer survival (hazard ratio ¼ 0.94; 95% confidence interval: 0.90 -0.98). 37 A margin size of 9 mm or more was associated with longest recurrence-free interval and a margin size of 11 mm or more was associated with the longest overall survival. To improve the standardization of margin assessment for sublobar resection, the IEL-CART protocol requires a measurement by each surgeon to be made in the operating room, in addition to the measurement routinely performed by pathologists on the surgical specimen.
Current Practice for Treatment of Early, Small NSCLCs
SBRT. Survival was assessed for clinical stage I NSCLC patients treated with SBRT (n ¼ 12) and compared with that of surgically treated patients (n ¼ 443). 38 No significant difference was found in the Kaplan-Meier NSCLC survival rates (90% vs. 92%, p ¼ 0.78) in this first report on SBRT-treated screen-diagnosed lung cancers.
Subsolid Nodules. The frequency of subsolid nodules, malignancy manifesting in them, and survival rates when treated was reviewed in the I-ELCAP and NLST databases and in systematic reviews of the literature. [12] [13] [14] [15] [16] [17] These extensive analyses made it clear that to correctly identify the nodule consistency, IELCART requires collection of pre-and post-treatment CT scans and central documentation of the imaging findings with a focus on the solid component of subsolid nodules.
Watchful Waiting. This option may be appropriate for patients with subsolid nodules, as lung cancers manifesting as such nodules have been shown to be slowgrowing, sometimes over decades. [12] [13] [14] [15] [16] [17] Questions as to nonsurgical alternatives are not yet well explored and patients with multiple nodules may not need to be provided with potentially curative surgery or SBRT. 39 Some untreated patients in I-ELCAP have had decades of good QoL without any treatment and were still fit for surgery or SBRT when older if the nodule continued to grow. However, not all patients may retain the same fitness level with increasing age. These issues are important for the physician-patient discussion about treatment alternatives and subsequent QoL because there is a dearth of information about this alternative.
QoL. Our systematic review of the QoL literature revealed that data on stage I NSCLC patients were very sparse. 40 Thus, additional analyses were performed on treated, screen-detected patients in the I-ELCAP database. 41, 42 These showed that physical health QoL significantly worsened from pre-to postsurgery after 1 year in women, but not in men, whereas mental health QoL marginally (but not significantly) improved for both. Compared to patients with sublobar resection, patients who underwent lobectomy had lower physical QoL but higher mental QoL scores after surgery. Further, physical and emotional well-being significantly improved after surgery among VATS patients, but worsened among thoracotomy patients.
Focus groups held with surgeons and patients further informed our choices of questions and QoL questionnaires. [43] [44] [45] For surgeons, choice of appropriate surgical procedure for each patient was a primary concern, followed by how to present the treatment plan to the patient. By contrast, patients placed their high levels of trust in their surgeon and did not feel the need to be very involved in the surgical decision-making process, but focused instead on postsurgical physical and mental health concerns. Patients specifically noted that they had not been prepared to manage the postsurgical side effects.
Our initial QoL instrument included the 12-item short-form survey, Functional Assessment of Cancer Therapy-Lung (FACT-L), Patient Health Questionnaire -4 (PHQ-4), and Medical Outcomes Study (MOS)-social support scale. [46] [47] [48] [49] Anxiety and depression symptom measures from the PHQ-4 and social support from the MOS-social support scale were also included. 48, 49 These measures allow us to gauge the association of pretreatment mental health and social support with either mitigating the negative impacts of lung cancer and lung cancer treatment or placing patients at greater risk for negative outcomes.
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Identification of Key Questions
As a result of these analyses, the IELCART team identified the following 6 questions to be addressed. 4. Is SBRT an acceptable alternative to surgical resection? 5. Is "watchful waiting" an alternative to immediate treatment for certain cases? 6. What are the consequences of the alternative treatment choices for the patients' QoL?
Feasibility Study
The goal was to examine the process of enrollment, patient and surgeon willingness to participate, to test the questionnaires, and to determine the frequency ratios of lobectomy to sublobar resection which are needed to determine the required sample size for the comparisons.
IELCART was designed as a multi-institutional study of alternative treatments, but the initial feasibility study focused on surgical treatment within the Mount Sinai Health System. A coordinator was assigned to each presurgical clinic. Once a patient had completed the discussion with the surgeon and was deemed to have clinical stage I NSCLC, the coordinator explained the study to the patient and asked the patient to sign the consent. It was important for the coordinator to be part of the presurgical team as this facilitated completion of the pre-and postsurgical questionnaires and further follow-up.
The feasibility study enrolled 206 patients with clinical stage I disease who had surgical resection, 133 women and 73 men (Table 1) . Lobectomy was performed for 89 (43.2%) and sublobar resection for 117 (56.7%). The NSCLCs manifested as a solid nodule in 157 (76.2%) and subsolid in 49 (23.8%). MLNR was performed in 173 (84.0%) of the patients; 11 had lymph node metastases, 8 with N1 and 3 with N2 disease. None had distant metastases.
Lobectomy and sublobar resection patients differed significantly in the presurgical findings as to average tumor size on CT (20.0 mm vs. 14.8 mm, p < 0.0001) and the frequency of the cancer manifesting as a solid nodule (84.3% vs. 70.1%, p ¼ 0.02). Postsurgical findings differed significantly as to frequency of MLNR (96.6% vs. 74.4%, p < 0.0001), average tumor size in the pathology specimen (20.5 mm vs. 13.2 mm, p < 0.0001), frequency of postsurgical T1aN0M0 disease (6.7% vs. 29.1%, p < 0.0001), and of pT1bN0M0 (34.8% vs. 47.0%, p ¼0.08).
Among the 206 patients, 35.0% had obtained a second opinion before surgery and relied on the surgeon as a primary source of information. Others also obtained information from the internet (23%), family/friends (13%), and other sources noted in Fig. 2 . In terms of what most influenced the patient choices, patients stated that both the surgeon's opinion (93%) and patient's opinion (93%) were extremely important, followed by their view that the chosen procedure would be best in terms of QoL (90%) (Fig. 3A) . The surgeons' pretreatment recommendations were mainly based on the location of the cancer (65%) and the tumor size (54%), followed by the other reasons listed in Fig. 3B .
Lessons Learned From the Feasibility Study
Some patients initially refused to participate because of the short time between the surgical clinic visit and the date of their surgery and/or because they were busy with life-altering decisions. To alleviate patients concerns, the coordinator obtained informed consent and then contacted these patients during subsequent presurgical visits to the hospital or at home before surgery. Also, two coordinators were assigned to the busiest surgical clinics to help each other so that multiple patients would be interviewed at the same time as well as those returning for follow-up visits.
To decrease the time required for obtaining the presurgical information, the QoL instruments were reviewed and simplified as they initially required approximately 30 minutes to administer. The FACT-L of the QoL questionnaire asked almost identical questions as the 12-item short-form survey so only the lung cancer portion of FACT-L was retained which has its own validated component subscale. The PHQ-4 and MOS social support survey were not changed. This shortened the average time to approximately 15 minutes.
Eligibility criteria were expanded based on the feasibility study, as it was recognized that an increasing number of patients are undergoing treatment for second and third new primary stage I NSCLCs. The expanded criteria include previously diagnosed patients for one or more pathologic stage I NSCLCs who were curatively treated at least 3 years before IELCART enrollment and had no mediastinal, hilar, or parenchymal metastases or recurrence since that earliest prior diagnosis. Our initial sample size target of 5000 patients was based on conservative assumptions with large unequal treatment allocation ratios between treatment groups and a long-term survival rate of 65% for lobectomy patients. Our preliminary results confirmed the increasing frequency of sublobar resection which had increased to 56% as compared with the prior frequency of 34% in I-ELCAP in 2011. 18 These results, assuming they persist as IELCART enrollment progresses, suggest that the required sample size may be markedly reduced as the treatment allocation ratio approaches equal between frequency of lobectomy and sublobar resection, together with well-documented higher survival rates up to 90% for early-stage disease instead of the conservative rate of 65% for clinical stage I NSCLCs. 9, 52 To detect survival differences between lobectomy and sublobar resection, the total sample size needed will increase as the allocation ratio increases. Assuming a frequency ratio of 1:1 for lobectomy:sublobar resection and the lobectomy NSCLC survival rate of 85%, the total sample size needed to detect a survival difference of less than 5% between these two options would require only 920 for 80% power or 1264 patients for 90% power, respectively, instead of 2095 and 2858 using the most conservation allocation ratio of 4:1 between lobectomy and sublobar resection, and survival rate of 65% for lobectomy patients. Including the additional comparison between lobectomy and SBRT, based on a ratio of lobectomy and SBRT of 5:1, the total sample size would be 2111 and 2924 for 80% and 90% power, respectively, instead of 4753. However, enrollment from other participating institutions may change these treatment ratios, 5000 remains as the target enrollment.
Based on the feasibility results, enrollment has now been extended to patients undergoing SBRT and watchful waiting and to other participating institutions.
Discussion
Although RCTs provide the highest level of evidence for comparing treatment alternatives, their implementation has historically been difficult, particularly when surgical treatments are being compared. [22] [23] [24] [25] [26] The last completed surgical RCT for stage I NSCLC was started in 1982, completed in 1988, and published in 1995. 3 In 2005, a new RCT was started in the United States using modern CT imaging and surgical approaches to answer the same question that had been addressed by the prior RCT 36 years ago. 10 Accrual difficulties also plagued RCTs for SBRT versus surgery in the United States and Japan. 11 A pooled analysis of two of the SBRTversus-surgery RCTs, which were closed because of lack of accrual, suggested that SBRT was better tolerated and might lead to better overall survival compared with surgery. 11 The ongoing VALOR trial comparing surgery with SBRT will likely take a long time to accrue sufficient patients. 53 RCTs typically enroll a highly selected subgroup of eligible patients, as many patients and/or physicians decide not to participate, particularly when deciding on curative treatment for a deadly disease. [43] [44] [45] Most of the 126 T1a and T1b patients in our feasibility study of the past year would have been eligible at our institution for the RCT comparing lobectomy to sublobar resection, whereas with multiple participating institutions it took 6 years to recruit 247 patients for the completed RCT and 12 years to recruit 692 for the currently ongoing RCT. 3, 10 These recruitment concerns, as well as the length of time and cost to complete an RCT, limit the external validity of its results as pointed out by Visvanathan et al. 26 Concerns about biases of cohort design, including selection bias, are addressed in IELCART by analyses that take into consideration known and unknown confounders. [34] [35] [36] Selection bias will be further addressed by comparing the long-term survival of all patients who consent to participate in IELCART with those who did not enroll in IELCART as shown in Fig. 1 .
The meta-analysis by Taioli et al. 27 highlighted the difficulty of deriving evidence from multiple independent studies. These limitations had been recognized earlier after the initial publication of the ELCAP results and were discussed at the International Conferences on Screening for Lung Cancer in 1999 and 2000. [7] [8] [9] 28 Recognition of these limitations had led the conference participants at that time to unanimously recommend the expansion of the prospective cohort design of ELCAP to I-ELCAP for further assessment of CT screening. The benefits of this design are amply shown by I-ELCAP, as with its updated protocol, it has to provide clinically relevant diagnostic and treatment information that has been incorporated in a continually updated CT screening program. [12] [13] [14] [15] [16] [17] [18] [19] [20] 30, [37] [38] [39] [40] [41] [42] [43] [44] [45] 54 The IELCART prospective cohort design provides a powerful paradigm for continued accrual of evidence on early lung cancer treatment. Once protocol procedures are integrated within a hospital's routine procedures, data can be collected on a broad spectrum of patients and thus allow continued evaluation of treatment alternatives. Also, IELCART integrates pre-and posttreatment QoL measures which are not routinely being used in the clinical care of stage I NSCLC patients.
IELCART may provide valuable information on future treatment alternatives as they are integrated into clinical care. It provides a platform for performing small-scale, innovative yet pragmatic treatment trials, including RCTs. One such "window-of-opportunity" treatment study of pazopanib therapy was very successful as patients could be recruited rapidly through the I-ELCAP collaborating sites. 55 This can be very useful for small phase II trial, such as providing localized immunotherapy followed by surgery. 56 Other trials in the future may focus on effects of different patient support interventions that can be provided after surgery.
IELCART examines the patient-physician decision process which has been shown in our focus sessions to play an important role in postoperative care. [43] [44] [45] Our focus groups found that stigma, anxiety, and depression are associated with poor QoL. Lung cancer patients found themselves alienated from family, friends, and society due to the consequences of smoking. Never-smokers with lung cancer report the same social stigma as smokers because the surrounding community assumes they have smoked at some point. Interventions that build or improve patient social networks might mitigate some of these psychosocial impacts. Future psychosocial interventions can be built into the IELCART process and tested.
Lung cancers manifesting as subsolid nodules are considered to be slower growing or more indolent, yet long-term outcome studies of cancers manifesting as subsolid nodules have only focused on surgically resected patients. [12] [13] [14] [15] [16] [17] Few reports are available on outcomes among patients under surveillance without invasive treatment, leading some to call for an RCT which randomly assigns patients to immediate surgery or "watchful waiting." As it may be unethical to randomly assign these patients to these alternatives, IELCART will serve as an excellent data source to rigorously examine the differences in outcomes as they naturally occur.
IELCART will provide useful multi-institutional evidence within its first several years and then continue to accumulate long-term evidence about the benefits of new diagnostic and therapeutic approaches, much like I-ELCAP has provided continuing evidence and insights on screening and long-term follow-up since its inception. 30 Given the limitations and lack of conclusiveness of the literature, as well as the obstacles encountered by surgical and radiotherapy RCTs, results from IELCART for small, early-stage NSCLCs will provide necessary information about the differential benefits of surgical and SBRT treatment. The IELCART study is not an experimental clinical trial, but rather a study of longterm outcomes and QoL of a cohort of patients on whom "usual care" before and after treatment are documented according to a common protocol with careful standardization of the data-collection process. IELCART uses information obtained in the context of ongoing, routine clinical practice under a common protocol and rigorous documentation of pretreatment plans and post-treatment implementation by the treating physician, as well as patient interviews before and after treatment. This will enable IELCART to both answer questions about optimal treatment in a rapid, thorough, timely, and less costly way with strong "external validity." It will also provide a platform for rapidly performing RCTs for treatment questions as novel approaches are introduced. 
